What Does a Glioblastoma Pathology Report Actually Tell You?
A glioblastoma pathology report describes the tumor's microscopic appearance, its WHO grade, and its molecular markers. The grade reflects how aggressive the tumor looks under a microscope. The molecular markers - IDH status, MGMT methylation, TERT mutation, and chromosome changes - describe the tumor's biology at the DNA level and show how it may respond to treatment.
Most people get the pathology report as a dense PDF in medical language. This guide goes through each major section so you know what your team is reading and what questions to ask before treatment begins.
What Does Grade 4 Mean?
All glioblastomas carry a WHO grade 4 classification - the highest grade in the World Health Organization's brain tumor grading system. Grade 4 reflects two microscopic changes the pathologist looks for: necrosis (dead tissue within the tumor) and microvascular proliferation (abnormal blood vessels caused by rapid tumor growth).
Under the 2021 WHO classification of central nervous system tumors, a grade 4 glioblastoma diagnosis can now be confirmed by molecular findings alone, even when the classic microscopic features are absent in a small or needle biopsy sample. This means molecular testing is now part of standard care.
IDH Status: The First Marker to Check
IDH stands for isocitrate dehydrogenase, a gene involved in normal cellular energy metabolism. Pathology reports classify brain tumors as either IDH-mutant (the gene carries an alteration) or IDH-wildtype (no alteration is present). This distinction changes the entire diagnostic category, not just a label on the report.
Under current WHO criteria, true glioblastoma is defined as IDH-wildtype. The American Brain Tumor Association explains that IDH-mutant high-grade gliomas - which were previously labeled glioblastoma under older classification systems - are now reclassified as astrocytoma, IDH-mutant, grade 4. This is a biologically distinct tumor type with a different prognosis and a different set of treatment and trial options.
If your report says IDH-mutant and your oncologist is treating it as glioblastoma, ask whether the current WHO classification has been used. If your report says IDH-wildtype, you have true glioblastoma under the current system. For more details on how these two categories differ in practice, see our guide on IDH-wildtype vs IDH-mutant glioblastoma: prognosis and treatment.
MGMT Methylation: How the Tumor Responds to Chemotherapy
MGMT stands for O-6-methylguanine-DNA methyltransferase. It is a DNA repair enzyme. When this gene is active in tumor cells, it repairs the genetic damage that temozolomide - the standard chemotherapy for glioblastoma - is designed to create. An active MGMT gene helps the tumor resist the chemotherapy.
When the MGMT promoter region is methylated, the gene shuts down. Tumor cells can no longer produce that repair enzyme efficiently. The National Brain Tumor Society notes that approximately 35 to 40 percent of IDH-wildtype glioblastomas have a methylated MGMT promoter. A landmark study in the New England Journal of Medicine found that patients with MGMT-methylated tumors receiving combined chemoradiation had a median survival of approximately 21.7 months, compared to approximately 15.3 months for those with unmethylated tumors on the same regimen.
If your report says "MGMT promoter methylated," this is a favorable finding. It does not guarantee the tumor will respond, but it indicates a higher likelihood that standard temozolomide-based treatment may work. If it says "unmethylated," your oncologist may explore alternative approaches, and this is one of the clearest reasons to check clinical trial eligibility at diagnosis rather than only at recurrence.
MGMT status also shapes treatment decisions in older patients. For patients over 65 or those who can't handle six weeks of chemoradiation, knowing MGMT status helps decide if a shorter radiation course with or without chemotherapy is the right choice.
TERT Promoter Mutation and EGFR Amplification
Two markers that appear less often in patient-facing explanations now carry formal diagnostic weight in the 2021 WHO classification: TERT promoter mutation and EGFR amplification.
TERT stands for telomerase reverse transcriptase. Cells rely on this enzyme to maintain the ends of chromosomes, which allows them to keep dividing. A TERT promoter mutation means the switch that activates this gene is abnormally stuck in the on position, helping tumor cells bypass the normal limits on cell division. TERT promoter mutations are very common in IDH-wildtype glioblastoma.
EGFR stands for epidermal growth factor receptor, a protein that drives cell growth and survival. EGFR amplification means the tumor carries extra copies of the gene that produces this protein. It is a common finding in IDH-wildtype GBM and is an active target in several clinical trials and experimental therapies.
According to the National Brain Tumor Society's overview of IDH-wildtype glioblastoma, the presence of TERT promoter mutation, EGFR amplification, or combined gain of chromosome 7 and loss of chromosome 10 can confirm a WHO grade 4 glioblastoma even when necrosis and microvascular proliferation are not visible in the biopsy sample. These markers are now part of confirming the diagnosis, not just characterizing the tumor after the fact.
For most patients, these markers currently confirm the diagnosis rather than directly change the immediate standard treatment choice. But knowing your tumor's EGFR status may matter when evaluating eligibility for newer targeted or immunotherapy-based trials.
Other Markers You May See on the Report
Depending on the pathology laboratory and which tests were done, the report may include additional markers. Here is what the most common ones mean:
- Ki-67 or MIB-1: A proliferation index. It shows what percentage of tumor cells were actively dividing at the time of biopsy. A higher number means faster growth. In grade 4 GBM, this rarely changes the immediate treatment plan, but it gives your team context about the tumor's speed and behavior.
- 1p/19q codeletion: Loss of specific regions on chromosomes 1 and 19. This finding is associated with oligodendroglioma, not glioblastoma. If your report shows 1p/19q codeletion alongside an IDH mutation, the diagnosis may actually be oligodendroglioma - a different tumor type with a more favorable prognosis and a distinct treatment approach.
- ATRX loss and TP53 mutation: Frequently found together in IDH-mutant astrocytomas. If these appear on your report alongside an IDH mutation, they further support a diagnosis of astrocytoma rather than glioblastoma under the current WHO system.
- PTEN loss or chromosome 10 deletion: Common in IDH-wildtype GBM. These do not typically change routine treatment, but may be relevant for certain clinical trial eligibility criteria.
Why a Second Neuropathology Review Can Change Everything
Receiving this diagnosis is one of the most frightening things a family can face. But before treatment begins, the pathology needs to be right.
Not all pathology laboratories run a full molecular panel by default. Not all reports are reviewed by neuropathologists who specialize in brain tumors. Some patients have started treatment on an incomplete molecular workup - without MGMT status confirmed, without IDH testing done, or without the 2021 WHO reclassification applied. When that happens, the treatment plan may be built on partial or outdated information.
A specialist neuropathology review can confirm the diagnosis category, verify whether the molecular panel is complete, identify atypical features that might point to a different tumor type, and sometimes change the treatment recommendation. This matters most in the weeks immediately after surgery, before the treatment plan is finalized. Our guide on what a glioblastoma second opinion includes outlines exactly what that review process should cover.
If the report feels incomplete, or if two oncologists are reading it differently, you can have the pathology and MRI reviewed by the Art of Healing Cancer team remotely. Slides and molecular data can be shared digitally. No travel is required, and expert review is most valuable before the first treatment decision is locked in.
Questions to Ask Your Oncologist About the Report
When you review the pathology with your neuro-oncologist, these questions will help you get the full picture:
- Is the IDH status confirmed as wildtype or mutant, and was the test performed directly on tumor tissue?
- Has MGMT promoter methylation status been tested, and what method was used?
- Were TERT promoter mutation and EGFR amplification tested?
- Is there a Ki-67 index on the report, and what does it suggest about tumor behavior?
- Are there any features on the pathology that seem atypical for standard glioblastoma?
- Was this report reviewed by a neuropathologist with specific brain tumor expertise?
The full molecular panel should ideally be completed within six weeks of surgery. Our article on why molecular testing should happen in the first six weeks after surgery explains what goes wrong when this window is missed - and what you can do to address it.
When to Talk to Your Doctor
Talk to your neuro-oncologist before treatment begins if any of these apply: the molecular panel on the report does not include IDH, MGMT, and TERT status; the diagnosis category has not been formally updated to match current WHO 2021 criteria; two physicians are interpreting the same report differently; or the report was reviewed without specialist neuropathology expertise. A second opinion on the pathology itself - separate from a second opinion on the treatment plan - is a reasonable and often clinically valuable step at this stage.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.